Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you recommend hypofractionated treatment for early stage, bilateral breast cancers?
Assume each primary meets ASTRO 2018 guidelines
Answer from: Radiation Oncologist at Community Practice
yes as i don't see any reason and have done multiple times
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
Agreed, key is to ensure fields are set up to prevent any potential overlap
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
Yes, check for overlap. Otherwise, there is no glaring contraindication.
Sign in or Register to read more
4383
4395
4397
Related Questions
Given the final publication of NSABP B-51, for which patients meeting trial eligibility would you still recommend regional nodal irradiation?
How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?
In patients with HER-2 positive breast cancer on pertuzumab/trastuzumab with newly developed asymptomatic brain metastases only, do you wait 3 weeks after administration of the targeted therapy to deliver SRS?
When utilizing hypofractionated radiotherapy in the post mastectomy setting, are the nodal regions dose painted to a different dose or the same dose as the chest wall/reconstructed breast?
In cT4aN0 triple negative breast cancer would you still recommend PMRT if pCR, ypT0N0(sn), after neoadj chemo is achieved?
What is your preferred sequencing of adjuvant chemotherapy and PMRT for node + breast cancer?
In what circumstances would you offer axillary re-irradiation after salvage axillary dissection?
How do the results of INSEMA and SOUND impact the decision of omitting SLND in young women with breast cancer and offering adjuvant RT to patients who would otherwise be candidates for omission?
For patients between 40-49 years old who undergo lumpectomy, how do you choose between offering PBI per the updated PBI guidelines or boosting based on boost guidelines?
Have the breast surgeons at your institution adopted the SOUND trial into their clinical practice?